ReadingResearchRadarInvestment framework
Sign in / Sign up
← Back to reading
NewsTopic · 谷歌生物制药AI代理3 min read·2026-10-17DisconfirmAI Editorial

Google Cloud Architects Explain Why Standard LLM Dispatching Fails in High-Compute Biotech Simulations

For tasks like protein folding, generic LLM agents often fail due to timeouts and context overflow. This article proposes a three-layer architecture separating cognitive orchestration from computational execution, using pass-by-reference data handling and asymmetric human approval to address latency and IP security in enterprise R&D automation.

ImportanceMaterialEvidenceE3 inspectableWrite-upQuick

Original publication time 2026-10-16

In production systems today, most AI agents operate as lightweight dispatchers: they parse a prompt, make an API call, retrieve a record, and hand back control. Their execution is fast, stateless, and cheap. However, workloads in biotechnology—such as folding a protein target, screening a 50,000-compound ligand library, or evaluating structure-activity relationships (SAR)—are not quick API lookups. They are sustained, stateful, GPU-bound simulations that run for minutes or even hours across specialized silicon. When a general-purpose large language model (LLM) endpoint attempts to coordinate such complex drug discovery workflows, the standard paradigm breaks: timeouts occur, context windows overflow with atomic coordinates, and proprietary chemical intellectual property risks exposure to external networks.

Schneider Larbi, Sr. Manager of Global Partner Technical Architecture at Google Cloud, and Chelsie Czop, Sr. Product Manager for AI Infrastructure, argue that building enterprise-grade research and development agents requires moving past the monolithic assistant model. They propose a three-layer architecture that separates cognitive orchestration (the brain) from computational execution (the muscle), anchoring both inside an enterprise governance plane. This reference pattern aims to solve scalability issues for high-compute autonomous agents in biopharma.

Sign in / Sign up
ReadingResearchRadarInvestment framework

In the execution layer, heavy scientific computations are handled by dedicated GPU infrastructure. For instance, protein folding is driven by ESMFold and generative design by GenMol, both deployed as NVIDIA Inference Microservices (NIMs) on Google Kubernetes Engine (GKE). To mitigate the cold-start penalty—the latency required to pull multi-gigabyte model weights from an image registry into VRAM—the architecture recommends maintaining warm pools (pinning at least one active node), preloading weights during pod initialization, and leveraging GKE for resilient scheduling. This approach trades manual CUDA kernel tuning for NVIDIA's pre-compiled, containerized runtimes, significantly reducing infrastructure engineering overhead while ensuring deterministic throughput.

In the cognitive layer, the system employs a hierarchical multi-agent structure with one lead orchestrator and two specialized sub-agents (Lead Optimization and Safety Screening). To prevent LLM performance degradation when ingesting massive arrays of 3D spatial coordinates, the architecture implements a 'pass-by-reference' strategy: raw structural data (like PDB files and docking poses) is written directly to cloud storage, while agents exchange only lightweight signed object URIs and high-level summaries. Furthermore, workflow logic is decoupled from biochemical reasoning: Gemini handles task planning and synthesis, while specialized Nemotron models on dedicated GPU nodes manage domain chemistry and pharmacological reasoning, preventing hallucinations in critical scientific details.

The enterprise governance layer introduces asymmetric autonomy. Recognizing that full autonomy in high-stakes R&D introduces unacceptable liability, while requiring approval for trivial steps creates friction, the architecture distinguishes between reversible and irreversible operations. Agents are allowed to autonomously perform reversible tasks like resolving chemical naming synonyms, pulling structural PDBs, or running preliminary Lipinski screens. However, irreversible actions—such as initiating multi-GPU docking runs, advancing a lead compound to wet-lab synthesis, or archiving a therapeutic program—require explicit human sign-off. Combined with cryptographic agent identity, centralized IAM gateways, and real-time prompt injection protection, this solution ensures data sovereignty and audit trails, allowing enterprises to focus on science rather than rebuilding compliance stacks for every project.

Sources

  • 原始出处cloud.google.com↗
Topic

谷歌生物制药AI代理

谷歌正通过重构底层架构与深化巨头合作，推动生物制药AI代理从通用LLM调度转向企业级高算力执行。针对蛋白质折叠等长时任务，谷歌提出“认知编排”与“计算执行”分离的三层架构，以解决超时与IP泄露问题；同时，默克（Merck）高达10亿美元的G…

5 steps1 piecesUpdated 2026-10-18 00:44

How it got here

  1. 2023-08-29Ginkgo Bioworks宣布与谷歌云达成五年协议，支付至少2.89亿美元使用Vertex AI构建药物发现模型，谷歌提供最高5600万美元资金。
  2. 2025-06-09Patsnap将Hiro-LS升级为Eureka LS，推出专为生物制药设计的AI代理平台，涵盖专利起草和抗体预测等功能。
  3. 2026-04-22默克（Merck）与谷歌云宣布多年期合作，价值高达10亿美元，将在研发、制造等环节全面部署基于Gemini Enterprise的代理生态系统。

What is still unsettled

  • 谷歌提出的三层架构能否有效降低中小型生物科技公司接入高性能AI计算的门槛？
  • 默克10亿美元投资的具体ROI（投资回报率）何时能在临床前阶段显现？
  • 随着AI代理深入监管严格的制药环节，如何建立统一的行业标准以验证AI输出的准确性与合规性？
Read the full topic →
Continue researching →